Active Digestion, Kidneys & Other Organs Cancer

Combining machine learning and human skin explant models to harness beneficial skin microbes to treat atopic dermatitis.

In plain English

AI plain-English summary

A single PhD project aims to replace the mouse models currently used to study eczema with human skin samples and computer simulations. Atopic dermatitis (eczema) affects millions, yet no cure exists. The condition is driven by an overgrowth of the bacterium *Staphylococcus aureus* on the skin, and heavy antibiotic use is fuelling resistance. Current animal models poorly mimic human disease and cause significant suffering. This project combines machine learning with human skin explants—biopsies of living skin kept in the lab—to design beneficial skin microbes that can displace *S. aureus* and prevent inflammatory damage. If successful, the work would replace animal models in eczema research, offering a more accurate and humane platform. It could also lead to a new class of targeted therapies that reconfigure the skin microbiome without antibiotics, reducing resistance. The computational models developed here could be adapted to study other microbiome-driven diseases. This is applied, translational research with a clear path to reducing animal use and improving treatment options for a common, debilitating condition.

View original technical description
Background: Atopic Dermatitis (AD) is a debilitating inflammatory skin condition that lacks a curative therapy. AD patients suffer dysbiosis of their skin microbiome, with domination by the pathogen Staphylococcus aureus, which drives immunopathology and disease progression. The extensive use of antibiotics for AD treatment has fostered the spread of antibiotic resistance, underscoring the urgent need for new therapies that can effectively combat AD and skin dysbiosis without promoting antibiotic resistance. Current AD Animal Model Drawbacks: The AD research landscape is dominated by animal models that inadequately recapitulate human disease and cause significant animal suffering. Our project aims to replace these models by integrating mathematical and machine learning models of the skin microbiome in AD with a more physiologically relevant experimental platform - a human skin explant model. PhD Project Goals: The aim of this NC3Rs PhD is to use these computational and human explant models to design and test beneficial skin microbes to eradicate Staphylococcus aureus and prevent inflammatory damage in AD. This research will achieve two significant outcomes: replacing the use of animals in AD research and developing a novel, targeted therapeutic approach that reconfigures the skin microbiome to prevent AD. We have support from labs around the world that currently use mouse models of AD who are eager to switch to our non-animal models. A Multidisciplinary Collaboration Based on a Commitment to the 3Rs: Our project is a collaboration between Dr Thomas Clarke (Department of Infectious Disease) and Prof. Reiko Tanaka (Department of Bioengineering) at Imperial College London. We will also collaborate with Dr Alex McCarthy (Department of Infectious Disease), an expert in human skin explants. Our collective expertise spans the microbiome, mathematical modelling, inflammatory and infectious disease models, and ex vivo human skin models. Our multidisciplinary team and expertise will ensure the feasibility and success of the project. Multidisciplinary Training and Support: Beyond its impact on the 3Rs and AD therapeutics, this PhD project will also provide exceptional multidisciplinary training, equipping the trainee with cutting-edge skills in the microbiome, human immunology, computational biology, and bioengineering. Our collaboration is well-established, all computational and wet lab models are in place, and we have state-of-the-art facilities. We believe our team is ideally positioned to provide the mentorship, training, and support to ensure the successful completion of this project.

View the original record at the funder ↗

Researchers

Reiko Tanaka (Co-Investigator)Thomas Clarke (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

Designing next-generation therapeutics for atopic eczema by controlling skin microbiome
CUtibacterium acnes metabolic engineering for Therapeutic Indole in situ delivery in atopic dermatitis SKIN
Anti-inflammatory microbes and their potential as topical therapeutics
Developing Human Skin Microbiota Models to Replace Rodent Studies and Explore Host-Microbe Interactions
Harnessing the health-associated dermal microbiota for improving skin health.

Original classification

Training Grant

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.